Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Clinical Chemistry
Emerging Technology
Immunoassays
Molecular Diagnostics
Pathology & AI
Proteomics
Quantum-Si launches next-generation single-molecule sequencing platform
According to the firm, the small footprint and lower price of the new platform are aimed at providing greater accessibility to high-resolution sequencing data.
December 20, 2022
Quantum-Si study demonstrates semiconductor-based single-molecule protein sequencing
The semiconductor chip contains millions of wells, enabling the cataloguing of many proteins in parallel and the understanding of how these proteins are modified at the single-molecule level.
October 14, 2022
NanoMosaic obtains rights to biomarker test for the diagnosis, prognosis of anesthesia-induced delirium, Alzheimer's
The test uses the Tessie system to alleviate bottlenecks in proteomics analysis and to enable protein interrogation as well as multiomics analysis within a single chip during one run.
October 12, 2022
Multiomics firm Pleno closes $40 million Series A financing
Pleno said its enabling technology leverages signal processing techniques from telecom to deliver ultra-high plexity, targeted biological information at high throughput.
October 12, 2022
OncoHost preparing launch of proteomics diagnostics platform for cancer, immunotherapy
The appointments come ahead of the company's launch of its AI-powered diagnostic platform called PROphet.
October 3, 2022
U.K. study: Blood test may predict long-COVID risk
A U.K. study led by researchers at University College London (UCL) shows that a blood test performed during the initial infection period may predict who is most likely to develop long COVID.
September 29, 2022
Most Popular
Quest launches long-COVID testing panels for consumers
Ohio, Kentucky doctors convicted in scheme to bill Medicaid for millions of dollars in unnecessary urinalysis testing
RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target
Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux
Patients prefer immediate test results, even when the news is bad
Quest Diagnostics offers suite of services for transplant patients and living donors
Thermo Fisher promotes new mass spectrometry instrument
The instrument is called Orbitrap Ascend Tribrid, and it offers capability for multiplexed proteomics and native protein characterization, according to Thermo Fisher. It can analyze more samples at lower concentrations, and features an ion source for calibration the company calls Auto-Ready.
August 28, 2022
Philips adopting proteomics results for patient management
The integration of proteomics results from the blood-based test -- along with the radiologic and patient history data currently used to determine treatment decisions -- can help create diagnostic efficiency for cancer care centers, Philips said.
June 29, 2022
Sera validates blood test in pregnant women at risk of bad outcomes
The PreTRM test can predict the risk of preterm birth in asymptomatic, singleton pregnancies to help identify infants more likely to be born before 32 weeks of gestation as well as those more likely to experience an increased length of neonatal hospital stay and severe adverse neonatal outcomes, the company noted.
May 21, 2020
Quest reports supportive data for new HDL cholesterol function test
The assay is a proteomic-based test of cholesterol efflux capacity (CEC), meaning the ability of HDL particles to accept cholesterol from white blood cells and begin the process of reverse cholesterol transport. The test assesses the function of apolipoproteins as a predictor of cholesterol efflux capacity, with results presented in a risk score. It was developed at Cleveland HeartLab, which was acquired by Quest in December 2017.
November 14, 2019
Page 1 of 1
